Qube Research & Technologies (QRT)
CMMB

Qube Research & Technologies (QRT)’s Chemomab Therapeutics CMMB Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11
Closed -$40 – 3418
2024
Q2 		$40 Hold
11
– – ﹤0.01% 3527
2024
Q1 		$34 Hold
11
– – ﹤0.01% 4236
2023
Q4 		$22 Hold
11
– – ﹤0.01% 4127
2023
Q3 		$39 Buy
+11
New +$51 ﹤0.01% 3834

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CMMB Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of Chemomab Therapeutics (CMMB) in Q3 2024, closing a stake of 11 shares — an estimated $40 sold.

Qube Research & Technologies (QRT) first reported a position in CMMB in Q3 2023 and held it in 4 quarters. The position peaked at $40 in Q2 2024. 15 funds tracked by Wall St. Rank hold CMMB as of Q3 2024.

  • Qube Research & Technologies (QRT) reported no remaining Chemomab Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 11 Chemomab Therapeutics shares in Q3 2024, an estimated $40.
  • Qube Research & Technologies (QRT) first reported a position in Chemomab Therapeutics in Q3 2023 and held it in 4 quarters.
  • Qube Research & Technologies (QRT)'s Chemomab Therapeutics position peaked at $40 in Q2 2024.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.